NCT02305238View on ClinicalTrials.gov

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

December 19, 2014

Primary Completion Date

December 22, 2016

Study Completion Date

December 20, 2017

Conditions
Wet Macular Degeneration
Interventions
DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Aflibercept 2mg is intravitreally injected.

Trial Locations (41)

491-8551

Ichinomiya

457-8510

Nagoya

467-8602

Nagoya

470-1192

Toyoake

289-2511

Asahi

285-8741

Sakura

963-8052

Kōriyama

737-0029

Kure

001-0016

Sapporo

060-0010

Sapporo

065-0031

Sapporo

650-0047

Kobe

300-0395

Inashiki-gun

310-0845

Mito

020-8505

Morioka

232-0024

Yokohama

783-8505

Nankoku

885-0051

Miyakonojō

395-8502

Iida

390-8621

Matsumoto

573-1191

Hirakata

570-8507

Moriguchi

589-8511

Sayama

569-1096

Takatsuki

520-2192

Ōtsu

101-8309

Chiyoda-ku

104-8560

Chuoku

193-0998

Hachiōji

181-8611

Mitaka

160-0023

Shinjuku-ku

162-8666

Shinjuku-ku

111-0051

Taito-ku

750-0061

Shimonoseki

755-8505

Ube

409-3898

Chūō

812-8582

Fukuoka

814-0180

Fukuoka

889-1692

Miyazaki

700-8558

Okayama

533-0024

Osaka

545-8586

Osaka

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY